Dyne Therapeutics, Inc. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Dyne Therapeutics, Inc. (DYN) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $2.01 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-07-29
- 2026-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $2.01M.
- 2026-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.55M.
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.63M.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.14M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2026-06-30 | $2.01M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $1.55M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $1.63M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.14M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.20M 10-Q · filed 2025-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |